GenMab A/S And AbbVie To Submit Data To Peer-Reviewed Medical Journal For Already-Released Phase 3 Trial Data Evaluating Epcoritamab For Adults With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Who Were Ineligible For Autologous Stem Cell Transplantation